Skip to main content
Log in

Policies to aid the adoption of personalized medicine

  • Comment
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Recent policy developments in the European Union and elsewhere aim to tackle some of the key issues responsible for the limited adoption of personalized medicine approaches so far.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. European Commission Working Document. [online], (2013).

  2. US Food and Drug Administration. [online], (2013).

  3. Maliepaard, M. et al. Nature Rev. Drug Discov. 12, 103–115 (2013).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

M.P. and C.N. are supported by the County of Salzburg and FP7-PIRSES- GA-2008-230661 or PMU-FFF-E-12/15/075.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Marisa Papaluca, Andre Terzic or Scott Waldman.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information S1 (box)

Further regulatory documents related to personalized medicine (PDF 61 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nofziger, C., Papaluca, M., Terzic, A. et al. Policies to aid the adoption of personalized medicine. Nat Rev Drug Discov 13, 159–160 (2014). https://doi.org/10.1038/nrd4257

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4257

  • Springer Nature Limited

This article is cited by

Navigation